Traws Pharma, Inc. Revenue from Contract with Customer, Including Assessed Tax
Traws Pharma, Inc. (TRAW) reported Revenue from Contract with Customer, Including Assessed Tax of $63.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-11-12
- Traws Pharma, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $63.00K, a 47.50% decline year-over-year.
- Traws Pharma, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $2.02M, a 316.91% increase year-over-year.
- Traws Pharma, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $120.00K.
- Traws Pharma, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $485.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month |
|---|---|---|---|
| 2019-09-30 | $63.00K 10-Q · filed 2019-11-12 | $2.08M derived: sum of 2 quarters · filed 2019-11-12 | $2.15M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.02M 10-Q · filed 2019-08-14 | $2.09M 10-Q · filed 2019-08-14 | |
| 2018-09-30 | $120.00K 10-Q · filed 2019-11-12 | $605.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.17M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $485.00K 10-Q · filed 2019-08-14 | $1.05M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |